The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease.

Gram-negative bacteria (GNB) and their endotoxin present a constant environmental challenge. Endotoxins can potently signal mobilization of host defenses against invading GNB but also potentially induce severe pathophysiology, necessitating controlled initiation and resolution of endotoxin-induced inflammation to maintain host integrity. The bactericidal/permeability-increasing protein (BPI) is a pluripotent protein expressed, in humans, mainly neutrophils. BPI exhibits strong antimicrobial activity against GNB and potent endotoxin-neutralizing activity. BPI mobilized with neutrophils in response to invading GNB can promote intracellular and extracellular bacterial killing, endotoxin neutralization and clearance, and delivery of GNB outer membrane antigens to dendritic cells. Tissue expression by dermal fibroblasts and epithelia could further amplify local levels of BPI and local interaction with GNB and endotoxin, helping to constrain local tissue infection and inflammation and prevent systemic infection and systemic inflammation. This review article focuses on the structural and functional properties of BPI with respect to its contribution to host defense during GNB infections and endotoxin-induced inflammation and the genesis of autoantibodies against BPI that can blunt BPI activity and potentially contribute to chronic inflammatory disease.

[1]  R. Heinrikson,et al.  Relation between binding and the action of phospholipases A2 on Escherichia coli exposed to the bactericidal/permeability-increasing protein of neutrophils. , 1987, Biochimica et biophysica acta.

[2]  A. Kung,et al.  A PHASE I SAFETY AND PHARMACOKINETIC STUDY OF A RECOMBINANT AMINO TERMINAL FRAGMENT OF BACTERICIDAL/ PERMEABILITY‐INCREASING PROTEIN IN HEALTHY MALE VOLUNTEERS , 1996, Shock.

[3]  P. Elsbach,et al.  Effects of the bactericidal/permeability-increasing protein of polymorphonuclear leukocytes on isolated bacterial cytoplasmic membrane vesicles , 1988, Infection and immunity.

[4]  A. Prince,et al.  Host-bacterial interactions in the initiation of inflammation. , 2001, Paediatric respiratory reviews.

[5]  P. Tobias,et al.  Lipopolysaccharide (LPS)-binding Proteins BPI and LBP Form Different Types of Complexes with LPS* , 1997, The Journal of Biological Chemistry.

[6]  J. Minei,et al.  Bactericidal/permeability-increasing protein (rBPI21) in patients with hemorrhage due to trauma: Results of a multicenter phase II clinical trial , 1999 .

[7]  R. Fichorova,et al.  Expression and function of bactericidal/permeability-increasing protein in human genital tract epithelial cells. , 2006, The Journal of infectious diseases.

[8]  Structural characterization of BPI-modulating 15 kDa proteins from rabbit polymorphonuclear leukocytes: Identification of a novel family of leukocyte proteins , 2005, Agents and Actions.

[9]  K. Rosendahl,et al.  Anti-neutrophil cytoplasmatic antibodies and lung disease in cystic fibrosis. , 2004, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[10]  M. Röllinghoff,et al.  Endotoxin-Induced Expression of Murine Bactericidal Permeability/Increasing Protein Is Mediated Exclusively by Toll/IL-1 Receptor Domain-Containing Adaptor Inducing IFN-β-Dependent Pathways1 , 2006, The Journal of Immunology.

[11]  I. Leiros,et al.  Cloning and analyses of a BPI/LBP cDNA of the Atlantic cod (Gadus morhua L.). , 2004, Developmental and comparative immunology.

[12]  J. Wieslander,et al.  Pseudomonas-induced lung damage in cystic fibrosis correlates to bactericidal-permeability increasing protein (BPI)-autoantibodies. , 2003, Clinical and experimental rheumatology.

[13]  J. Weiss,et al.  Bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP): structure, function and regulation in host defence against Gram-negative bacteria. , 2003, Biochemical Society transactions.

[14]  P. Elsbach,et al.  An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Weiss,et al.  Determinants of the inhibitory action of purified 14-kDa phospholipases A2 on cell-free prothrombinase complex. , 1994, The Journal of biological chemistry.

[16]  P. Limburg,et al.  Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features. , 1998, The American journal of medicine.

[17]  R. Romero,et al.  Antimicrobial peptides in amniotic fluid: defensins, calprotectin and bacterial/permeability-increasing protein in patients with microbial invasion of the amniotic cavity, intra-amniotic inflammation, preterm labor and premature rupture of membranes , 2003, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[18]  R. Inman,et al.  Comparative microbicidal activity of synovial fluid on arthritogenic organisms , 1996, Clinical and experimental immunology.

[19]  R. Munford,et al.  Deacylation of Purified Lipopolysaccharides by Cellular and Extracellular Components of a Sterile Rabbit Peritoneal Inflammatory Exudate , 1999, Infection and Immunity.

[20]  Carl Nathan,et al.  Points of control in inflammation , 2002, Nature.

[21]  J. Lipton,et al.  Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides. , 1982, The Journal of clinical investigation.

[22]  M. Ernst,et al.  Anti‐neutrophil cytoplasmic antibodies directed against the bactericidal/permeability‐increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N‐terminal regions important for the anti‐microbial and lipopolysaccharide‐binding activity of BPI , 2000, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[23]  P. Elsbach,et al.  The Carboxyl-terminal Domain of Closely Related Endotoxin-binding Proteins Determines the Target of Protein-Lipopolysaccharide Complexes* , 2002, The Journal of Biological Chemistry.

[24]  K. Fellermann,et al.  Autoantibodies Against the Bactericidal/Permeability-Increasing Protein from Inflammatory Bowel Disease Patients Can Impair the Antibiotic Activity of Bactericidal/Permeability-Increasing Protein , 2004, Inflammatory bowel diseases.

[25]  J. Weiss,et al.  Monomeric endotoxin:protein complexes are essential for TLR4-dependent cell activation , 2005, Journal of endotoxin research.

[26]  C. Bingle,et al.  PLUNC: a novel family of candidate host defence proteins expressed in the upper airways and nasopharynx. , 2002, Human molecular genetics.

[27]  G. Schmitz,et al.  The genomic organization of the genes for human lipopolysaccharide binding protein (LBP) and bactericidal permeability increasing protein (BPI) is highly conserved. , 1997, Biochemical and biophysical research communications.

[28]  S. Carroll,et al.  Biochemical Characterization of Recombinant Fusions of Lipopolysaccharide Binding Protein and Bactericidal/Permeability-increasing Protein , 1997, The Journal of Biological Chemistry.

[29]  Ross-Russell,et al.  Anti‐neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability‐increasing protein (BPI) and cystic fibrosis lung disease , 1999, Clinical and experimental immunology.

[30]  A. Griffioen,et al.  Bactericidal/permeability-increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. , 2000, Blood.

[31]  W. Nauseef,et al.  Synergy between Extracellular Group IIA Phospholipase A2 and Phagocyte NADPH Oxidase in Digestion of Phospholipids of Staphylococcus aureus Ingested by Human Neutrophils1 , 2005, The Journal of Immunology.

[32]  C. E. Ooi,et al.  Individual and synergistic effects of rabbit granulocyte proteins on Escherichia coli. , 1994, The Journal of clinical investigation.

[33]  M. Glauser,et al.  Competition between bactericidal/permeability-increasing protein and lipopolysaccharide-binding protein for lipopolysaccharide binding to monocytes. , 1993, The Journal of infectious diseases.

[34]  A. Lennartsson,et al.  All‐trans retinoic acid‐induced expression of bactericidal/permeability‐increasing protein (BPI) in human myeloid cells correlates to binding of C/EBPβ and C/EBPε to the BPI promoter , 2006 .

[35]  G. Soma,et al.  Cloning and Characterization of the Homolog of Mammalian Lipopolysaccharide-Binding Protein and Bactericidal Permeability-Increasing Protein in Rainbow Trout Oncorhynchus mykiss1 , 2002, The Journal of Immunology.

[36]  J. Cohen,et al.  Protective effects of a recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in an animal model of gram-negative sepsis. , 1995, The Journal of infectious diseases.

[37]  R. Ulevitch,et al.  Structure and function of lipopolysaccharide binding protein. , 1990, Science.

[38]  M. Sakai,et al.  Molecular cloning of a novel bactericidal permeability-increasing protein/lipopolysaccharide-binding protein (BPI/LBP) from common carp Cyprinus carpio L. and its expression. , 2003, Molecular immunology.

[39]  S. Carroll,et al.  Anti‐neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders , 1996, Clinical and experimental immunology.

[40]  T. Pufe,et al.  Detection of natural peptide antibiotics in human nasolacrimal ducts. , 2001, Investigative ophthalmology & visual science.

[41]  V. Cerundolo,et al.  BPI–ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram‐negative bacterial infections , 2003, Clinical and experimental immunology.

[42]  O. Levy,et al.  Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[43]  W. Gross,et al.  BPI‐ANCA of pediatric cystic fibrosis patients can impair BPI‐mediated killing of E. coli DH5α in vitro , 2004, Pediatric pulmonology.

[44]  R. Munford.  Detoxifying endotoxin: time, place and person. , 2005, Journal of endotoxin research.

[45]  A. Eerenberg,et al.  Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. , 1995, The Journal of infectious diseases.

[46]  Zhao,et al.  Catalase and α‐enolase: two novel granulocyte autoantigens in inflammatory bowel disease (IBD) , 1998 .

[47]  D Eisenberg,et al.  Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. , 1997, Science.

[48]  J. Holopainen,et al.  Group IIA phospholipase A2 content in tears of patients having photorefractive keratectomy , 2003, Journal of cataract and refractive surgery.

[49]  S. Opal,et al.  Relative concentrations of endotoxin-binding proteins in body fluids during infection , 1994, The Lancet.

[50]  J. Weiss,et al.  Determinants of activation by complement of group II phospholipase A2 acting against Escherichia coli , 1996, Infection and immunity.

[51]  J. Bramson,et al.  Protection from endotoxemia by adenoviral-mediated gene transfer of human bactericidal/permeability-increasing protein. , 2004, Blood.

[52]  R. Munford,et al.  Deacylation of Lipopolysaccharide in Whole Escherichia coli during Destruction by Cellular and Extracellular Components of a Rabbit Peritoneal Inflammatory Exudate* , 1999, The Journal of Biological Chemistry.

[53]  F. Re,et al.  Specific High Affinity Interactions of Monomeric Endotoxin·Protein Complexes with Toll-like Receptor 4 Ectodomain* , 2007, Journal of Biological Chemistry.

[54]  A. Toivanen,et al.  BPI-ANCA is found in reactive arthritis caused by Yersinia and Salmonella infection and recognise exclusively the C-terminal part of the BPI molecule. , 2000, Scandinavian journal of rheumatology.

[55]  A. Wiik,et al.  Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis. , 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[56]  A. Šedivá,et al.  Antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein detected in children with cystic fibrosis inhibit neutrophil-mediated killing of Pseudomonas aeruginosa. , 2003, Microbes and infection.

[57]  I. W. Devoe,et al.  RELEASE OF ENDOTOXIN IN THE FORM OF CELL WALL BLEBS DURING IN VITRO GROWTH OF NEISSERIA MENINGITIDIS , 1973, The Journal of experimental medicine.

[58]  M. Doerfler,et al.  Antibacterial proteins of granulocytes differ in interaction with endotoxin. Comparison of bactericidal/permeability-increasing protein, p15s, and defensins. , 1995, Journal of immunology.

[59]  G. van Zandbergen,et al.  ANCA against the bactericidal/permeability increasing protein (BPI-ANCA) can compromise the antibiotic function of BPI in a Wegener's granulomatosis patient. , 2003, Clinical and experimental rheumatology.

[60]  A. Müller,et al.  Bactericidal/Permeability-Increasing Protein Is Expressed by Human Dermal Fibroblasts and Upregulated by Interleukin 4 , 2003, Clinical Diagnostic Laboratory Immunology.

[61]  L. Thijs,et al.  PHARMACOKINETICS OF A RECOMBINANT AMINO TERMINAL FRAGMENT OF BACTERICIDAL/PERMEABILITY INCREASING PROTEIN (rBPI21) AFTER LIVER SURGERY IN RATS AND HUMANS , 1998, Shock.

[62]  M. Hodson,et al.  Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. , 1996, QJM : monthly journal of the Association of Physicians.

[63]  G. King,et al.  Bactericidal/permeability‐increasing protein's signaling pathways and its retinal trophic and anti‐angiogenic effects , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[64]  Xia Li,et al.  Lipopolysaccharide deacylation by an endogenous lipase controls innate antibody responses to Gram-negative bacteria , 2005, Nature Immunology.

[65]  Y. Collan,et al.  Bactericidal/permeability-increasing protein in lacrimal gland and in tears of healthy subjects , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.

[66]  E. Rietschel,et al.  Invited review: Bacterial lipopolysaccharides and innate immunity , 2001 .

[67]  T. Pufe,et al.  Antimicrobial peptides are expressed and produced in healthy and inflamed human synovial membranes , 2002, The Journal of pathology.

[68]  M. Saake,et al.  Expression and Antimicrobial Function of Bactericidal Permeability-Increasing Protein in Cystic Fibrosis Patients , 2006, Infection and Immunity.

[69]  J. Malm,et al.  The bactericidal/permeability‐increasing protein (BPI) is membrane‐associated in azurophil granules of human neutrophils, and relocation occurs upon cellular activation , 2000, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[70]  U. Gullberg,et al.  Biosynthesis, processing and sorting of neutrophil proteins: insight into neutrophil granule development , 1997, European journal of haematology.

[71]  G. Hoffman,et al.  Antineutrophil cytoplasmic antibodies. , 1998, Bulletin on the rheumatic diseases.

[72]  F. Moosig,et al.  ANCA against bactericidal/permeability-increasing protein, azurocidin, calprotectin and defensins in rheumatic and infectious diseases: prevalence and clinical associations. , 2003, Clinical and experimental rheumatology.

[73]  R. Munford.  Invited review: Detoxifying endotoxin: time, place and person , 2005 .

[74]  S. Carroll,et al.  The endotoxin‐binding bactericidal/permeability‐increasing protein (BPI): a target antigen of autoantibodies , 2001, Journal of leukocyte biology.

[75]  R. Medzhitov,et al.  Toll-dependent selection of microbial antigens for presentation by dendritic cells , 2006, Nature.

[76]  M. Wilson,et al.  Effects of bacterial endotoxins on neutrophil function. , 1985, Reviews of infectious diseases.

[77]  K. Jolley,et al.  Activation of human dendritic cells by the PorA protein of Neisseria meningitidis , 2004, Cellular microbiology.

[78]  I. Reardon,et al.  Structural and functional properties of a phospholipase A2 purified from an inflammatory exudate. , 1986, Biochemistry.

[79]  C. Aebi,et al.  Autoantibodies directed against bactericidal/permeability‐increasing protein in patients with cystic fibrosis: association with microbial respiratory tract colonization , 2000, The Pediatric infectious disease journal.

[80]  H. Odeberg,et al.  Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. , 1978, The Journal of biological chemistry.

[81]  D. White,et al.  TLR4 inactivation and rBPI(21) block burn-induced myocardial contractile dysfunction. , 2002, American journal of physiology. Heart and circulatory physiology.

[82]  B. Beutler,et al.  Innate immune sensing and its roots: the story of endotoxin , 2003, Nature Reviews Immunology.

[83]  R. Grenman,et al.  Group II phospholipase A2 in nasal fluid, mucosa and paranasal sinuses. , 1997, Acta oto-laryngologica.

[84]  P. Elsbach,et al.  p15s (15-kD antimicrobial proteins) are stored in the secondary granules of Rabbit granulocytes: implications for antibacterial synergy with the bactericidal/permeability-increasing protein in inflammatory fluids. , 1997, Blood.

[85]  K. Mulholland,et al.  New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine in Children Aged 16–24 Months , 2007, The Pediatric infectious disease journal.

[86]  O. Hrusak,et al.  Antineutrophil cytoplasmic autoantibodies (ANCA) in children with cystic fibrosis. , 1998, Journal of Autoimmunity.

[87]  Phil Barton,et al.  Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial , 2000, The Lancet.

[88]  T. Ganz.  Antimicrobial proteins and peptides in host defense. , 2001, Seminars in respiratory infections.

[89]  S. Carroll,et al.  Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria , 1994, Infection and immunity.

[90]  W. Ammons,et al.  rBPI(10—193) is secreted by CHO cells and retains the activity of rBPI21 , 2004, Journal of endotoxin research.

[91]  W. Buurman,et al.  Antagonistic effects of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein on lipopolysaccharide-induced cytokine release by mononuclear phagocytes. Competition for binding to lipopolysaccharide. , 1993, Journal of immunology.

[92]  A. Nanbo,et al.  Bactericidal/permeability‐increasing protein promotes complement activation for neutrophil‐mediated phagocytosis on bacterial surface , 2001, Immunology.

[93]  M. Doerfler,et al.  Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils , 1991, The Journal of experimental medicine.

[94]  C. Svanborg,et al.  Cytokine responses during mucosal infections: role in disease pathogenesis and host defence. , 1999, Current opinion in microbiology.

[95]  W. Buurman,et al.  Bactericidal/permeability-increasing protein, a lipopolysaccharide-specific protein on the surface of human peripheral blood monocytes. , 1996, The Journal of infectious diseases.

[96]  S. Jones,et al.  Bactericidal/permeability‐increasing protein (BPI) is an important antigen for anti‐neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis , 1995, Clinical and experimental immunology.

[97]  O. Levy,et al.  Extracellular accumulation of potently microbicidal bactericidal/permeability-increasing protein and p15s in an evolving sterile rabbit peritoneal inflammatory exudate. , 1995, The Journal of clinical investigation.

[98]  M. H. Terry,et al.  Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. , 1991, NIPH annals.

[99]  J. Levy.  The human immunodeficiency virus and its pathogenesis. , 1988, Infectious Disease Clinics of North America.

[100]  I. Olsson,et al.  Cellular and subcellular localization of the bactericidal/permeability-increasing protein of neutrophils. , 1987, Blood.

[101]  P. Elsbach,et al.  Separation of sublethal and lethal effects of the bactericidal/permeability increasing protein on Escherichia coli. , 1990, The Journal of clinical investigation.

[102]  P. Kinnunen,et al.  Modulation of the Activity of Secretory Phospholipase A2 by Antimicrobial Peptides , 2003, Antimicrobial Agents and Chemotherapy.

[103]  B. Giroir,et al.  Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis , 1997, The Lancet.

[104]  H. Rosenberg,et al.  The bactericidal/permeability-increasing protein (BPI) is present in specific granules of human eosinophils. , 1998, Blood.

[105]  R. D. de Winter,et al.  In vivo interaction of endotoxin and recombinant bactericidal/permeability-increasing protein (rBPI23): hemodynamic effects in a human endotoxemia model. , 2002, The Journal of laboratory and clinical medicine.

[106]  S. V. van Deventer,et al.  Inflammatory bowel disease is associated with increased mucosal levels of bactericidal/permeability-increasing protein. , 1996, Gastroenterology.

[107]  D. Lill-Elghanian,et al.  bactericidal / permeability-increasing protein fragment of lipid A required for binding of a recombinant Characterization of the structural elements in , 1994 .

[108]  Y. Lin,et al.  Protective effects of a recombinant N-terminal fragment of bactericidal/permeability increasing protein on endotoxic shock in conscious rabbits. , 1994, Shock.

[109]  L. Aiello,et al.  Differential effects of bactericidal/permeability-increasing protein (BPI) analogues on retinal neovascularization and retinal pericyte growth. , 2002, Investigative ophthalmology & visual science.

[110]  P. Elsbach,et al.  High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide , 1992, Infection and immunity.

[111]  J. Verhoef,et al.  Human granulocytes express a 55-kDa lipopolysaccharide-binding protein on the cell surface that is identical to the bactericidal/permeability-increasing protein. , 1993, Journal of immunology.

[112]  C. Serhan.  Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. , 2007, Annual review of immunology.

[113]  F. Dallegri,et al.  Tissue injury in neutrophilic inflammation , 1997, Inflammation Research.

[114]  R. Schumann,et al.  Similar organization of the lipopolysaccharide-binding protein (LBP) and phospholipid transfer protein (PLTP) genes suggests a common gene family of lipid-binding proteins. , 1997, Genomics.

[115]  D. Bainton.  Neutrophilic leukocyte granules: from structure to function. , 1993, Advances in experimental medicine and biology.

[116]  R. Dellinger,et al.  Inflammation and coagulation: implications for the septic patient. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[117]  R. Munford,et al.  Endotoxin-binding Proteins Modulate the Susceptibility of Bacterial Endotoxin to Deacylation by Acyloxyacyl Hydrolase* , 2007, Journal of Biological Chemistry.

[118]  R. Munford,et al.  Detoxification of bacterial lipopolysaccharides (endotoxins) by a human neutrophil enzyme. , 1986, Science.

[119]  O. Levy,et al.  Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein. , 1999 .

[120]  M. N. Marra,et al.  Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. , 1990, Journal of Immunology.

[121]  C. E. Ooi,et al.  A 25-kDa NH2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein. , 1987, The Journal of biological chemistry.

[122]  B. Gibson,et al.  Biochemical and Functional Characterization of Membrane Blebs Purified from Neisseria meningitidis Serogroup B* , 2005, Journal of Biological Chemistry.

[123]  A. Lennartsson,et al.  AML-1, PU.1, and Sp3 regulate expression of human bactericidal/permeability-increasing protein. , 2003, Biochemical and biophysical research communications.

[124]  A. Lennartsson,et al.  A murine antibacterial ortholog to human bactericidal/permeability‐increasing protein (BPI) is expressed in testis, epididymis, and bone marrow , 2005, Journal of leukocyte biology.

[125]  C. Serhan,et al.  Lipid-Derived Mediators in Endogenous Anti-Inflammation and Resolution: Lipoxins and Aspirin-Triggered 15-epi-Lipoxins , 2002, TheScientificWorldJournal.

[126]  T. H. The,et al.  AUTOANTIBODIES AGAINST NEUTROPHILS AND MONOCYTES: TOOL FOR DIAGNOSIS AND MARKER OF DISEASE ACTIVITY IN WEGENER'S GRANULOMATOSIS , 1985, The Lancet.